For patients with TBI-related ICH, a shorter mannitol and tranexamic acid administration interval may contribute to VTE risk

Background: After the CRASH-3 trial, the debate on tranexamic acid (TXA) has never ended. As significant parts in traumatic brain injury-related intracranial hemorrhage pharmacologic therapies, we hypothesized that the shorter mannitol and TXA administration interval might increase those patients' VTE risk. Methods: A retrospective study was conducted. Data were extracted through the China Trauma Rescue & Treatment Association database. Finally, 712 cases were included in the data analysis: the VTE group (n=45) and the non-VTE group (n=667). Then, a t-test, Pearson Chi-square test, and logistic regression were performed. Results: the VTE group indicates significant aging (57.11±9.35, p=0.001), shorter mannitol and TXA administration interval (12.62±8.72, p=0.002), longer LHS (20.48±2.64,p<0.000), and higher D-dimer (6.05±2.59, p=0.001). By further logistic regression, the mannitol and TXA administration interval presents a relation with VTE occurrence with β=-0.053, OR=0.948, and P=0.004. Conclusion: The mannitol and tranexamic acid administration interval might be an independent VTE risk for patients with TBI-related intracranial hemorrhage.